Abstract c-Myc is frequently overexpressed in tumors and plays an important role in the regulation of cancer metabolism. Hypoxia-inducible factor-1 (HIF1), the master regulator of the hypoxic response, enhances tumorigenesis and influences metabolism via upregulation of the glycolytic pathway and suppression of mitochondrial respiration. Together, deregulated Myc and HIF1 cooperate to lend metabolic advantages to proliferating cancer cells and contribute to the Warburg effect. Here we show that overexpression of Myc significantly stabilizes the a subunit of HIF1 (HIF1a) under normoxic conditions and enhances HIF1a accumulation under hypoxic conditions in cells. Posttranscriptional regulation of HIF1a by Myc led to the induction of HIF1a gene targets. Normoxic HIF1a protein expression was also dependent on Myc. Functionally, HIF1a expression was required for Myc-induced anchorage-independent growth and cell proliferation. Mycdependent stabilization of HIF1a involved either disruption of binding to the VHL complex or posttranslational protein modifications. Taken together, our findings uncover a previously uncharacterized regulatory relationship between Myc and HIF1 that has important implications for cancer metabolism and development. Cancer Res; 72(4); 1-9. Ó2011 AACR.
Introduction
Breast cancer is the most common malignancy of women worldwide and targets 13% of women in the United States (National Cancer Institute). The c-myc oncogene, which encodes the transcription factor c-Myc, contributes to many forms of cancer and was one of the first genes found to be amplified in breast cancer (1) . Studies suggest that at least 15% to 20% of breast cancers present with significant amplification of c-myc and that overexpression of c-Myc likely occurs in an even greater number of tumors through other mechanisms (2) . Animal model studies have confirmed that constitutive Myc expression in the mammary gland is oncogenic in transgenic mice (3) . Microarray studies have exposed Myc as a weak yet pleiotropic transcription factor, possessing the ability to activate or repress 5% to 10% of all genes by 1.5-fold or more (4) . Whereas these target genes vary greatly depending on the cellular context, commonly targeted processes include the cell cycle, metabolism, and apoptosis (5) .
In transformed cells, Myc promotes glycolysis by activating glycolytic enzymes (6, 7) . Tumor cells often exhibit increased rates of glycolysis, even in the presence of adequate oxygen concentrations (the Warburg effect); although, increased rates of glycolysis normally occur under hypoxic conditions (8, 9) . Hypoxia-inducible factor-1 (HIF1) is the key mediator of the hypoxic response in cellular tissues, comprised of a constitutively expressed HIF1b subunit and an oxygen-responsive HIF1a subunit (10, 11) . In oxygenated tissues, HIF1a has a very short half-life (10, 12) . Rapid turnover is mediated through the hydroxylation of two prolines at amino acids 402 and 564, performed by oxygen-dependent prolyl hydroxylases (13) (14) (15) ; reviewed in ref. 16 ). Prolyl-hydroxylation of HIF1a leads to ubiquitination by the Von Hippel-Lindau (VHL) E3 ubiquitin ligase and degradation via the 26S proteasome (reviewed in refs. 17, 18) . In a hypoxic environment, HIF1a becomes stabilized (19, 20) , although, in some instances, HIF1a can be stabilized under normoxia as well (reviewed in refs. 21, 22) . HIF1a is commonly expressed in cancers, as tumor microenvironments suffer from hypoxia owing to an incomplete vasculature.
Studies have reported HIF1-induced opposition of Myc under hypoxia when Myc is expressed at nontumorigenic levels. Studies have also revealed the cooperation of HIF1 and deregulated Myc under hypoxia (23) (24) (25) (26) . However, our data show that Myc regulates HIF1a expression under both normoxia and hypoxia, and that HIF1a expression represents an important component of Myc function. Our results show a novel and complex relationship between Myc, HIF1a, and tumor development.
Materials and Methods

Cell culture, transfection, and retroviral infection
Retroviral producing PhoeNX cells and breast cancer lines MCF7 and T47D were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% FBS. IMEC epithelial cells were cultured in 1:1 DMEM/F12 medium supplemented with 5% FBS and other factors (27) . Retroviral infection was carried out using PhoeNX cells. Briefly, PhoeNX cells were transfected with 7 mg DNA using LipoD293 (Signagen) according to manufacturer's instructions. Virus was harvested from the culture medium 2 days later and used to infect recipient IMECs. Cells were selected 2 days later and maintained in 150 mg/mL hygromycin (Calbiochem) to select for LXSH vectors (LXSH, LXSH-Myc). Hypoxic conditions were induced by culturing cells for 2 hours in a sealed hypoxia chamber (Billups Rothenberg) after flushing with a mixture of 1% O 2 , 5% CO 2 , and 94% N 2 . Hypoxic conditions were also induced by the addition of CoCl 2 (Sigma) at a concentration of 200 mmol/L for 3 hours. We refer to the ambient oxygen concentration as normoxic (95% air, 5% CO 2 ). Although the ambient oxygen concentration is not the physiologic normoxic state, this is a frequently used convention in the literature.
Cell counts
Cells were plated at 1 Â 10 4 per well in 6-well plates on day 0. Cells were maintained as stated earlier. Cells were harvested each day for 4 days and counted using a hemacytometer. At least 100 cells were counted. The experiment was conducted in duplicate on 2 separate occasions. Knockdown cell growth curves were achieved by plating cells at 1 Â 10 4 per well, transfecting with HIF1a and nontargeting control siRNA 24 hours later (day 1), and counting cells for 3 days posttransfection. The experiment was conducted in duplicate on 2 separate occasions.
Soft agar assay
Assays were done in 6-well plates in duplicate on 2 separate occasions. The lower layer of agar consisted of 2 mL IMEC medium containing 10% FBS and 0.6% Noble Agar (USB). The upper layer consisted of 2 mL IMEC medium containing 10% FBS, 0.3% Noble Agar, and 4 Â 10 4 cells. Agar at 50 C was mixed with medium at 37 C, plated, and left to set for 10 minutes. Plates were fed every other day with 250 mL IMEC medium containing 10% FBS. After 10 days, undivided cells and colonies were scored using a reticle, measuring the greatest diameter. A total of 100 cells were counted per well.
Real-time PCR
RNA was extracted from log-phase cells using TRIzol (Invitrogen) according to manufacturer's instructions. RNA was converted into cDNA using the iScript cDNA Synthesis Kit (Bio-Rad) and PCR was done using iQ SYBR Green Supermix and the CFX96 Real-Time PCR Detection System (Bio-Rad). Primers used were glyceraldehyde-3-phosphate dehydrogenase (GAPDH) GCTCAGACACCATGGGGAAGGTGAAG and GCTG-ATGATCTTGAGGCTGTTGTCATAC; Myc CGAGGAGGA-GAACTTCTACCAGC and CGAGAAGCCGCTCCACATACAG-TCC; HIF1a ACAGTATTCCAGCAGACTCAA and CCTACTGC-TTGAAAAAGTGAA; HK2 GGATGATTGCCTCGCATCTGC and GGAACTCTCCGTGTTCTGTCC; ALDOA CCATGCCCTACCAA-TATCCAGC and GGTGGTAGTCTCGCCATTTGTCC; eNOS GGAGAGATCCACCTCACTGTAGC and CCTTTGCTCTCAAT-GTCATGC; BGN GGAACATGAACTGCATCGAGATGG and CGATCATCCTGATCTGGTTGTGG; VHL CCTTTGGCTCTT-CAGAGATGC and GGTCTTTCTGCACATTTGGGTGG; CUL2 GCAGAAGATTCAACACTACACTTGC and CCTTGCTGTAT-TCTTCCCAGTACC; RBX1 GCAGCGATGGATGTGGATACC and CCTGTCGTGTTTTGAGCCAGC; Elongin B CCACAAGAC-CACCATCTTCACG and CGTGCTGTTTGACTGGTGAAGC; Elongin C CCTATGGTGGCTGTGAAGGACC and GCAGTT-CCAGTGCAATTTCAGG.
Western blots
Cells were lysed in F-Buffer and cell extracts were normalized for protein content. Proteins were resolved by SDS-PAGE, transferred to polyvinylidene difluoride membrane, and immunoblotted with antibody in 5% milk. Antibodies used include monoclonal anti-HIF1a (Novus Biologicals), polyclonal antiHIF1a (Novus Biologicals), monoclonal anti-VHL (BD Biosciences), polyclonal anti-VHL (Novus Biologicals), antihydroxyproline-564-specific-HIF1a (kindly provided by R. Freeman), monoclonal anti-c-Myc antibody (C-33; Santa Cruz), polyclonal anti-c-Myc antibody (N262; Santa Cruz), anti-b-tubulin (Santa Cruz), monoclonal anti-CUL2 (Santa Cruz), polyclonal anti-CUL2 (Abcam), polyclonal anti-Rbx1 (Santa Cruz), polyclonal anti-Elongin B (Santa Cruz), monoclonal anti-Elongin C (BD Biosciences), and polyclonal antiElongin C (Novus Biologicals). Immunoprecipitations were carried out by complexing Protein A/G-Plus Agarose beads with 1 mg of antibody for 1 hour and then mixing the beads with cell extract overnight. ImageJ (NCBI) was used to quantitate protein expression levels.
Cycloheximide assay
Cells were plated in 6-well plates and treated with cycloheximide (CHX) 24 hours postplating. CHX was added at a concentration of 50 mg/mL to the cells at 20-minute intervals. Hypoxic extracts were made by treating cells with 200 mmol/L CoCl 2 for 3 hours prior to CHX treatment. Protein extracts were prepared as previously described. HIF1a and Myc half-lives were calculated after quantitating protein and normalizing to b-tubulin.
siRNA
Experiments involving siRNA were conducted by transfecting HIF1A, c-myc, or nontargeting siRNA (Dharmacon) at 2 mmol/L in 6-well plates according to manufacturer's instructions. Cells were replated 24 hours following transfection for soft agar analysis. RNA and protein was harvested for analysis 24 
Results
Myc enhances accumulation of hypoxia regulator HIF1a
We have previously shown that overexpression of Myc in TERT-IMECs leads to a partial oncogenic transformation with an increased proliferation rate and anchorage-independent growth (28) . It is important to note that Myc expression in the transduced IMECs is similar to Myc protein levels found in breast cancer cell lines T47D and MDA-231 and, hence, represents physiologically relevant expression (28) . Whole genome expression analysis revealed that the most significantly enriched Myc-induced cluster corresponded to angiogenesis and vascularization (Supplementary Table; data available on request). Previous studies have linked angiogenesis to Myc in a transgenic model (29, 30) . Furthermore, many genes involved in these pathways have been scored as potential direct Myc target genes in microarrays. However, the most prominent regulator of angiogenesis is HIF1, which coordinately controls the expression of a large number of genes in the pathway. Therefore, we explored whether the strong induction of an angiogenic program is due to activation of HIF1a, instead of a direct effect of Myc.
To assess a potential role for HIF1 in the induction of an angiogenic gene response, we examined the levels of HIF1a protein in vector and Myc-overexpressing cells under normoxic (95% air, 5% CO 2 ) or hypoxic conditions (1% O 2 , 5% CO 2 , 94% N 2 ). As expected, there were very low levels of HIF1a in IMECs cultured under normoxic conditions, and the level was induced substantially under hypoxia. Surprisingly, we found that overexpression of Myc enhances the accumulation of HIF1a under normoxic conditions to a significant level. Moreover, overexpression of Myc exaggerates HIF1a accumulation under hypoxic conditions (Fig. 1A) . On average, HIF1a expression in Myc-overexpressing cells under normoxia is 10 times more than in vector IMECs (Fig. 1B) . We determined whether the increase in protein expression is due to an increase in transcription of the HIF1a gene by carrying out quantitative real-time (RT) PCR under normoxic and hypoxic conditions. We found that HIF1a is not transcriptionally induced by hypoxia, as expected, or by Myc (Fig. 1C) . Myc transcription is also not affected by hypoxia. These data suggested that Mycenhanced HIF1a expression is posttranscriptionally regulated.
We treated the vector control IMECs and IMEC-Myc cells with the proteasome inhibitor MG132 to block protein degradation and assess the total amount of HIF1a protein being translated under normoxia and hypoxia. As expected, the enhanced level of HIF1a under hypoxia is an effect of stabilization and not increased translation, as protein levels become equal when degradation is inhibited (Fig. 1D) . We found that, even though normoxic HIF1a is stabilized significantly by Myc, treatment with MG132 leads to further stabilization, indicating that there is some ongoing degradation in IMEC-Myc cells. In contrast, all of the HIF1a protein seemed to be fully stabilized under hypoxia in Myc-overexpressing cells because MG132 treatment gives no further enhancement.
Because HIF1 protein levels are primarily controlled by proline hydroxylation and interaction with the VHL E3 ligase, we tested whether the enhanced HIF1a expression in response to Myc under normoxia is due to the loss of proline hydroxylation. We used an antibody specific to the prolyl hydroxylation site (hydroxy-P564 HIF1a) to measure the extent of modification relative to HIF1a protein levels. We confirmed that HIF1a is prolyl hydroxylated in normoxic cells, and hydroxylation is suppressed under hypoxia (Fig. 1A) . To compare HIF1a modification with or without high levels of Myc, we treated cells with MG132 to prevent turnover of HIF1a and quantitated the level of prolyl hydroxylation to total HIF1a levels. We find that the ratio of prolyl hydroxylated to total HIF1a is identical with high and low Myc ( Fig. 1D and 1E ), thus the elevated levels of HIF1a are not due to the suppression of proline hydroxylation. Furthermore, prolyl hydroxylation is sensitive to reactive oxygen species (ROS), but quenching of ROS with N-acetylcysteine had no effect on the Myc-dependent accumulation of HIF1a (Supplementary Figure) .
We wanted to explore whether HIF1a protein expression is induced by Myc in other cell types. We measured protein levels in myc À/À Rat1 fibroblasts before and after stable reconstitution with mouse c-Myc (Fig. 1F) . As in IMECs, HIF1a protein levels are enhanced with Myc reconstitution under normoxic conditions, and Myc dramatically exaggerates HIF1a levels in hypoxia. As expected, there are no changes in HIF1a mRNA levels due to Myc expression (Fig. 1G ).
HIF1 induces its target gene expression
We next looked at the expression levels of HIF1a target genes to determine whether there is a functional downstream effect of enhanced HIF1a by Myc under normoxia in IMECs. We transiently transfected vector and Myc-overexpressing IMECs with siRNAs against HIF1A, c-myc, or a nontargeting control and achieved depletion at the RNA level ( Fig. 2A) . By RT-PCR, we found that glycolytic enzymes HK2 and ALDOA, nitric oxide synthase eNOS, and collagen fibril assembly proteoglycan BGN are all transcriptionally upregulated in Mycoverexpressing cells under normoxia (Fig. 2B) . Of these genes, HK2 is the only one known to be a direct binding target of both HIF1a and Myc. Consistent with this, these genes are downregulated in response to HIF1a depletion. These genes are also all downregulated in response to Myc knockdown, suggesting that there is indeed a functional downstream effect of enhanced HIF1a expression by Myc.
Myc induces HIF1 expression in breast cancer cells
We also explored whether HIF1a protein levels are dependent on Myc in human cancer cells. To this end, we examined HIF1a and Myc in the breast cancer cell lines T47D and MCF7 (Fig. 3A) . MCF7 cells have 3.5-fold higher Myc protein levels than T47D and have significant constitutive HIF1a protein under normoxic conditions, whereas T47D cells have virtually undetectable levels (Fig. 3B) . As in other cell types, Myc protein levels largely correspond to mRNA levels, whereas HIF1a mRNA levels are equivalent between cell lines (Fig. 3C) . To test whether HIF1a protein levels are Myc dependent in MCF7 cells, we used siRNA to deplete native Myc. We found that the loss of Myc led to a corresponding reduction in HIF1a, suggesting that HIF1a expression is dependent on Myc in MCF7 cells (Fig. 3D) .
Myc stabilizes HIF1a protein
Because we found elevated HIF1a protein with no change in mRNA levels (Fig. 1) , we hypothesized that the substantial accumulation of HIF1a in response to Myc under normoxia and hypoxia could be due to a decrease in its rate of degradation. We treated IMECs and IMEC-Myc cells with CHX to block protein synthesis and assessed HIF1a protein levels at 20 minutes intervals under both normoxic and hypoxic conditions (Fig. 4) . As previously described, HIF1a has an extremely short half-life under normoxia (t 1/2 < 7 minutes) and is barely detectable in the vector cells. However, we found that overexpression of Myc under normoxic conditions significantly stabilizes HIF1a protein (t 1/2 ¼ 56 minutes). This stabilization can account for most or all of the enhanced HIF1a protein levels in IMEC-Myc. In contrast, Myc protein turnover is similar between control and Myc-overexpressing cells. Under hypoxia, HIF1a protein is stabilized (t 1/2 ¼ 42 minutes) as previously described (11, 29, 30) . However, Myc-overexpression further stabilizes HIF1 (t 1/2 > 90 minutes), which can account for the hyperinduction of HIF1a in hypoxic IMEC-Myc cells.
Myc enhances accumulation of VHL complex components
We next sought to determine other possible mechanisms that could account for Myc-induced stabilization of HIF1a protein. Because HIF1a prolyl hydroxylation is maintained in IMEC-Myc cells (Fig. 1E) , we turned our focus to the next step in the normoxic regulation of HIF1a: the recognition and ubiquitination of prolyl-hydroxylated HIF1a by the VHL complex. We hypothesized a role for Myc in rendering the VHL complex less functional. We considered that Myc could be regulating expression levels of the components themselves, promoting protein modifications that could impact the formation of the VHL complex or affecting external cofactors that Hypoxic cell extracts were made after incubating cells for 2 hours in a hypoxia chamber with 1% oxygen. Normoxic HIF1a blots are shown at a longer exposure than the hypoxic HIF1a blots. Norm, normoxia, Hypo, hypoxia. B, average HIF1a protein expression, normalized to b-tubulin, was quantitated using 3 independent cell extract sets. Expression levels are normalized to normoxic vector. C, real-time RT-PCR was done using RNA harvested from IMECs and primers specific to HIF1A, c-myc, and GAPDH in triplicate. Average c-myc and HIF1a RNA levels are normalized to GAPDH and then normalized to their respective normoxic vectors. D, IMECs were treated with proteasome inhibitor MG132 under normoxic and hypoxic conditions. Western blot analyses were carried out with equivalent amounts of protein using anti-HIF1a and anti-b-tubulin antibodies. E, after treatment with MG132, average hydroxy-P564 HIF1a protein expression was determined in comparison with total HIF1a protein expression under normoxia and hypoxia. F, Western blot analyses of myc À/À rat fibroblasts (vector or Myc reconstituted) were done as described above. G, real-time RT-PCR was carried out using RNA harvested from myc À/À rat fibroblasts and primers specific to HIF1A, c-myc, and GAPDH in triplicate. Average c-myc and HIF1A RNA levels are normalized to GAPDH. HIF1A is normalized to its normoxic vector. c-myc is normalized to normoxic myc À/À (Myc) as vector cells express no c-myc RNA. Error bars, SD. influence function. We first assessed protein levels to determine whether Myc might be downregulating one or more of the VHL components, which would destabilize complex formation. Quite unexpectedly, we found that Myc significantly enhances the accumulation of all of the VHL complex components under both normoxic and hypoxic conditions (Fig. 5A) . Furthermore, except for a 2-fold induction of VHL RNA, the regulation seemed to be entirely posttranscriptional (Fig. 5B) . As with HIF1a previously, we wanted to determine whether the expression of these VHL complex components is induced by Myc in other cell types. We again measured protein levels in myc À/À Rat1 fibroblasts before and after stable reconstitution with mouse c-Myc. As in IMECs, the protein levels of the VHL components are enhanced in response to elevated Myc expression under both normoxic and hypoxic conditions (Fig. 5C ). Of note, both VHL and Elongin B not only change in abundance but also shift in migration in SDS-PAGE ( Fig. 5A and C) , suggesting that there may be Myc-induced changes in protein modification.
HIF1a exhibits reduced binding to the VHL complex in
Myc-overexpressing cells Because we found that HIF1a is stabilized even in the presence of upregulated VHL complex components, we hypothesized that the VHL complex is less effective at recognizing and targeting HIF1a for degradation in Myc-overexpressing cells. To assess the association between the VHL complex and HIF1a, we carried out immunoprecipitations with different components (VHL, CUL2, and Elongin C) and with HIF1a. Indeed, we found that there is less binding of HIF1a to VHL complexes in IMEC-Myc cells compared with vector cells under both normoxia and hypoxia (Fig. 6A) . Normoxic association between HIF1a and CUL2, Elongin C, and VHL are each reduced to only about 30% of the association seen in vector cells. This reduction may account for a significant portion of the HIF1a stabilization in IMEC-Myc cells. 2) targeting HIF1A or c-myc. RNA was isolated 48 hours posttransfection. Real-time RT-PCR was done using primers specific to HIF1A, c-myc, and GAPDH in triplicate. Average RNA levels were normalized to GAPDH and then normalized to their respective normoxic vectors. B, real-time RT-PCR was done using primers specific to ALDOA, HK2, eNOS, BGN, and GAPDH in triplicate. Average RNA levels were normalized to GAPDH and then normalized to their respective normoxic vectors. Error bars, SD. CUL2, Elongin C, and VHL, we found that there were also apparent changes in VHL complex component associations in IMEC-Myc cells compared with vector cells (Fig. 6B) . This suggested that, in addition to associating less with HIF1a, there may be fewer functional VHL E3 ligase complexes formed in Myc-overexpressing cells.
HIF1a expression is critical for Myc-induced soft agar growth and proliferation One of the most important questions we wanted to explore is whether or not HIF1a accumulation contributes to Myc-induced oncogenic transformation. To address this question, we carried out siRNA depletion experiments and assessed their effects on Myc-induced anchorage-independent growth, which is an established hallmark of transformation. We transiently transfected IMECs and IMEC-Myc with siRNAs against HIF1A, c-myc, or a nontargeting control. Myc depletion served as a positive control because soft agar growth is Myc dependent, and loss of Myc expression should ablate the ability of the cells to undergo anchorage-independent growth. We achieved depletion at the protein level for both Myc and HIF1a (Fig. 7A and B) . Consistent with the Myc dependence of HIF1a accumulation, depleting Myc from the IMEC-Myc cells reduced the HIF1a protein level nearly back to that found in the parental IMECs. We plated transfected cells in soft agar 24 hours posttransfection with siRNA and scored for growth 10 days later. The IMEC-Myc cells transfected with the nontargeting control grew into colonies as expected (Fig. 7C) . Depletion of Myc predictably led to an almost complete loss of colony growth. Strikingly, the loss of HIF1a expression was equally as effective in blocking anchorage-independent growth, as HIF1a depletion almost completely eliminated soft agar colony formation (Fig. 7C) . Vector control IMECs do not grow in soft agar and are therefore not represented (28) . These data showed that expression of HIF1a is a critical component of Mycinduced anchorage-independent growth. In support of these data, multiple studies have shown that the knockdown of HIF1a in tumor cells suppresses tumor growth (33) (34) (35) .
Beyond anchorage-independent growth, we showed previously that Myc overexpression also enhances the overall proliferation rate of IMECs compared with vector control cells (28) . Because of the importance of HIF1a expression for Mycinduced soft agar growth, we considered that HIF1a might also influence proliferation rates. We measured IMEC growth rates after transfection with HIF1A siRNA and compared them with IMECs transfected with nontargeting siRNA under normoxia (Fig. 7D) . Depletion of HIF1a expression greatly reduces the Figure 7 . HIF1a expression is affected by Myc levels and is necessary for anchorage-independent and log-phase growth. A and B, IMECs were transfected with nontargeting siRNA or siRNAs (1 or 2) targeting HIF1A or c-myc. Cell extracts were made 48 hours posttransfection. Western blot analyses were done with equivalent amounts of cell extracts using anti-HIF1a, anti-c-Myc, and anti-b-tubulin antibodies. Average Myc and HIF1a protein expression, normalized to b-tubulin, were quantitated using 3 independent cell extract sets. Expression levels for Myc and HIF1a protein were normalized to their respective vectors. C, IMECs transfected with nontargeting siRNA or siRNAs (1 or 2) targeting HIF1A or c-myc were plated in soft agar 24 hours posttransfection. The number of colonies per 100 plated Myc-overexpressing cells were counted and measured after 10 days in 2 independent experiments. Vector cells do not grow in soft agar and are therefore not included in the analysis. D, cell proliferation rates were measured by counting equivalently plated cells that had been transfected at day 1 with either HIF1A or nontargeting siRNA under normoxia. The graph shows the mean cell number for each day for duplicate experiments. Error bars, SD. Similar results were found for independent siRNAs.
Discussion
In this study, we have explored a previously uncharacterized relationship between Myc and HIF1a expression under both normoxic and hypoxic conditions: Myc-dependent induction of HIF1 protein levels. Previous studies have shown interactions between Myc and HIF1 regulation and function, both synergistic and antagonistic. For example, in cells expressing physiologically normal levels of Myc, HIF1 has been found to functionally oppose Myc activity by disrupting Myc repression of CDKI p21 (38, 39) . In addition to antagonizing Myc function through interaction, HIF1 also counters Myc-mediated regulation of mitochondrial biogenesis (4, 25, (40) (41) (42) . Whereas Myc itself promotes mitochondrial biogenesis and oxidative phosphorylation, HIF1 activates target genes that impair mitochondrial respiration. On the other hand, HIF1 and deregulated Myc cooperate to induce glycolysis in both normoxic and hypoxic tissues (23, 24, 26, 43) . Studies suggest that Myc overexpression disrupts the sensitive stoichiometry normally governing HIF1 regulation of Myc. Normoxic cooperation of these transcription factors contributes to the Warburg effect, a metabolic phenotype of aerobic glycolysis often seen in cancers.
We report that overexpression of Myc induces a dramatic enhancement in the stability of HIF1a protein under normoxia and also increases stability under hypoxia. A previous study reported that knockdown of Myc in a multiple myeloma cell line decreases HIF1a expression (44), but we provide the first evidence that overexpression of Myc in nontransformed epithelial and fibroblastic cells single handedly induces the accumulation of HIF1a. Furthermore, we show that this induction is entirely posttranscriptional and that it results in the upregulation of HIF1a target genes. We show that Myc is also required for the posttranscriptional accumulation of HIF1a protein in MCF7 breast cancer cells. At the functional level, we show that HIF1a expression is essential for both Myc-induced anchorageindependent growth and Myc-induced proliferation.
The mechanism of Myc-induced HIF1a stabilization remains unresolved. On the basis of measurement of HIF1a hydroxy-P564 levels after blocking protein turnover, it seems that there is no reduction in hydroxylation with high Myc expression (Fig. 1E) . The primary effect we observed is that Myc posttranscriptionally upregulates the expression of VHL complex components. Furthermore, we find that HIF1a association with the VHL complex in cells overexpressing Myc is substantially reduced compared with vector control cells. The decreased interaction between HIF1a and the VHL complex likely contributes significantly to the enhanced accumulation of HIF1a protein. This could be due to an unknown modification of HIF1a or to inactivation of the VHL complex E3 ligase activity. We find evidence of disruption of VHL complex protein stoichiometry and possible posttranslational modifications of VHL and Elongin B. Further characterization of changes in the VHL complex in response to high Myc expression will be required to resolve these questions.
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